| Arbutus Biopharma is a therapeutic solutions company focused on discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus (HBV) infection. Co.'s HBV pipeline consists of multiple drug candidates, with differing and complementary mechanisms of action. The candidates include: RNAi 1.0 (ARB-1467), which is Co.'s main RNA Interference (RNAi) HBV candidate designed to block production of the viral proteins including HBV surface antigen expression in patients with HBV; RNAi 2.0 (ARB-1740), Co.'s second RNAi HBV candidate; and Capsid Inhibitors (AB-423 & AB-506), which is being developed as oral therapeutics for the treatment of chronic HBV infection. We show 30 historical shares outstanding datapoints in our coverage of ABUS's shares outstanding history.|
Understanding the changing numbers of ABUS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ABUS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ABUS by allowing them to research ABUS shares outstanding history
as well as any other stock in our coverage universe.